Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection

[1]  S. Shen,et al.  A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI) , 2016, BMC Cancer.

[2]  Yudong Qiu,et al.  Preoperative Enteral Nutritional Support in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma , 2015, Medicine.

[3]  R. Cetin-Atalay,et al.  Molecular Biology of Liver Cancer , 2015 .

[4]  Junfei Jin,et al.  Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection , 2015, Oncotarget.

[5]  M. Schwartz,et al.  Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. , 2015, Annals of surgery.

[6]  S. Shen,et al.  The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma , 2015, BMC Cancer.

[7]  N. Mukhopadhyay,et al.  Astrocyte elevated gene‐1 and c‐Myc cooperate to promote hepatocarcinogenesis in mice , 2015, Hepatology.

[8]  Y. Gusev,et al.  βII‐Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin , 2015, Hepatology.

[9]  S. Thorgeirsson,et al.  MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism. , 2014, Cancer research.

[10]  L. Rimsza,et al.  Clinical Significance of MYC Expression and/or “High-grade” Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas: A SWOG S9704 Correlative Study , 2014, The American journal of surgical pathology.

[11]  F. Tacke,et al.  Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. , 2013, Biochimica et biophysica acta.

[12]  M. Namba,et al.  Human hepatocyte carcinogenesis , 2013, International journal of oncology.

[13]  F. Tacke,et al.  Novel findings in an old model: Overexpression of c-myc in hepatocytes promotes the activation of hepatic stellate cells and facilitates the onset of liver fibrosis , 2013 .

[14]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[15]  D. Zimonjic,et al.  Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: Potential prospects for combined targeted therapeutics , 2012, International journal of oncology.

[16]  X. Wang,et al.  Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer , 2010, Proceedings of the National Academy of Sciences.

[17]  F. Biasi,et al.  Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. , 2010, Molecular aspects of medicine.

[18]  Chien-Ru Liu,et al.  Targeting c-Myc as a novel approach for hepatocellular carcinoma. , 2010, World journal of hepatology.

[19]  Xiao‐Yu Yin,et al.  Mechanisms and Influence of Octreotide-Induced Regulation of Somatostatin Receptor 2 on Hepatocellular Carcinoma , 2009, Chemotherapy.

[20]  S. Thorgeirsson,et al.  Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. , 2009, Cancer research.

[21]  G. Evan,et al.  Distinct thresholds govern Myc's biological output in vivo. , 2008, Cancer cell.

[22]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[23]  B. Hoffman,et al.  Apoptotic signaling by c-MYC , 2008, Oncogene.

[24]  B. Peng,et al.  [Changes in TGF-beta1/Smads signaling pathway in rats with chemical hepatocarcinogenesis]. , 2008, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[25]  Soyoung Lee,et al.  FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. , 2007, Genes & development.

[26]  G. Evan,et al.  Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. , 2006, Cancer cell.

[27]  S. Thorgeirsson,et al.  Application of comparative functional genomics to identify best-fit mouse models to study human cancer , 2004, Nature Genetics.

[28]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[29]  P. Liang,et al.  Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. , 2004, World journal of gastroenterology.

[30]  S. Pelengaris,et al.  The many faces of c-MYC. , 2003, Archives of biochemistry and biophysics.

[31]  X. Guan,et al.  Prognostic significance of c‐myc and AIB1 amplification in hepatocellular carcinoma , 2002, Cancer.

[32]  G. Evan,et al.  Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.

[33]  S. Thorgeirsson,et al.  Acceleration of c-myc-induced hepatocarcinogenesis by Co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signaling disruption. , 1999, The American journal of pathology.

[34]  Chi V. Dang,et al.  c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.

[35]  G. Prendergast,et al.  c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. , 1995, Oncogene.

[36]  S. Thorgeirsson,et al.  Transgenic Mouse Model for Synergistic Effects of Nuclear Oncogenes and Growth Factors in Tumorigenesis: Interaction of c-myc and Transforming Growth Factor α in Hepatic Oncogenesis , 1993 .

[37]  Tara L. Kieffer,et al.  Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis , 2009 .

[38]  M. Yuen,et al.  Expression of c‐Myc, c‐Fos, and c‐Jun in hepatocellular carcinoma , 2001, Cancer.

[39]  S. Thorgeirsson,et al.  Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. , 1993, Cancer research.